View by Specialty

Trending

AdobeStock_Carrots_1200x630
November 18, 2024
1 min read
Save

CDC: 1 dead in multistate outbreak of E. coli linked to organic carrots

Pulmonary Vascular Disease News

SPONSORED CONTENT
Save
SPONSORED CONTENT
December 16, 2022
3 min read
Save

Catheter-directed fibrinolysis safe in intermediate-high-risk pulmonary embolism

Catheter-directed fibrinolysis safe in intermediate-high-risk pulmonary embolism

In adults with intermediate-high-risk pulmonary embolism, catheter-directed fibrinolysis plus anticoagulation appears safe and was associated with favorable imaging-based findings compared with anticoagulation monotherapy, data show.

SPONSORED CONTENT
December 05, 2022
2 min read
Save

Macitentan demonstrates safety in real-world patients with pulmonary arterial hypertension

Macitentan showed no new safety signals in patients with pulmonary arterial hypertension from two real-world datasets, according to a study published in Pulmonary Circulation.

Trending

AdobeStock_Carrots_1200x630
November 18, 2024
1 min read
Save

CDC: 1 dead in multistate outbreak of E. coli linked to organic carrots

SPONSORED CONTENT
November 04, 2022
2 min watch
Save

VIDEO: Speaker discusses ‘nuanced’ guidance on VTE management

VIDEO: Speaker discusses ‘nuanced’ guidance on VTE management

NASHVILLE, Tenn. — In this Healio exclusive, Samantha Pettigrew, MD, discusses CHEST’s 2021 update to its clinical guidelines on using anticoagulation for venous thromboembolism at the CHEST Annual Meeting.

SPONSORED CONTENT
October 26, 2022
3 min read
Save

E-cigarettes confer endothelial dysfunction similar to traditional cigarettes

E-cigarettes confer endothelial dysfunction similar to traditional cigarettes

Reduced flow-mediated dilation was observed among both e-cigarette and traditional cigarette users, but circulating levels of certain inflammatory and thrombotic mediators differed between the two groups, researchers reported.

SPONSORED CONTENT
October 25, 2022
2 min watch
Save

VIDEO: Takeaways from CHEST 2022 with Parth Rali, MD

VIDEO: Takeaways from CHEST 2022 with Parth Rali, MD

NASHVILLE, Tenn. — In this Healio exclusive, Parth Rali, MD, spotlights education on mechanical circulatory support devices at the CHEST Annual Meeting.

SPONSORED CONTENT
October 23, 2022
1 min read
Save

Patients with scleroderma should receive regular pulmonary arterial hypertension screening

Patients with scleroderma should receive regular pulmonary arterial hypertension screening

SAN DIEGO — Pulmonary arterial hypertension’s prevalence and rate of progression in patients with connective tissue diseases should make regular screening a priority, according to a speaker at the Congress of Clinical Rheumatology West.

SPONSORED CONTENT
October 19, 2022
2 min watch
Save

VIDEO: Takeaways from CHEST 2022 with Belinda Natalia Rivera-Lebron, MD, MS

VIDEO: Takeaways from CHEST 2022 with Belinda Natalia Rivera-Lebron, MD, MS

NASHVILLE, Tenn. — In this Healio exclusive, Belinda Natalia Rivera-Lebron, MD, MS, highlights the role of artificial intelligence as a tool for acute pulmonary embolism risk stratification.

SPONSORED CONTENT
October 18, 2022
2 min read
Save

Patients with pulmonary hypertension at high risk for acute kidney injury

Patients with pulmonary hypertension at high risk for acute kidney injury

NASHVILLE, Tenn. — Patients admitted with background secondary pulmonary hypertension may have an increased risk for acute kidney injury and adverse outcomes, according to a presenter at the CHEST Annual Meeting.

SPONSORED CONTENT
October 18, 2022
1 min read
Save

Patients with IPF who experience in-hospital cardiac arrest face increased mortality rate

Patients with IPF who experience in-hospital cardiac arrest face increased mortality rate

NASHVILLE, Tenn. — Idiopathic pulmonary fibrosis appeared associated with increased mortality rates and worse outcomes among in-hospital cardiac arrest survivors, according to study results presented at the CHEST Annual Meeting.

SPONSORED CONTENT
October 17, 2022
2 min read
Save

Nintedanib maintains safety, efficacy long-term in patients with SSc-associated ILD

Nintedanib maintains safety, efficacy long-term in patients with SSc-associated ILD

Nintedanib maintains its safety and efficacy for up to 3 years in patients with systemic sclerosis-associated interstitial lung disease, according to data published the Annals of the Rheumatic Diseases.

View more
Healio Minute Subscribe to Healio Minute emails You're now subscribed to Healio Minute Emails
Healio Minute Subscribe to Healio Minute emails You're now subscribed to Healio Minute Emails